Microbot Medical, which continues to build a network of global leaders in the endovascular interventional space for the LIBERTY® Robotic System, today announced that Vincent Vidal, M.D., PhD, has joined its Scientific Advisory Board (SAB).
Dr. Vidal is a world-leading advocate and distinguished expert of embolization techniques. He is the head of Interventional Radiology in the Imaging Department of Timone Hospital (Marseille, France) and Professor at the Faculty of Medicine and Director at the Experimental Interventional Imaging Laboratory (LiiE) at the Aix-Marseille University, where his research and clinical work are focused on embolization. Dr. Vidal received both his M.D. and PhD from the School of Medicine of Aix-Marseille University, and he is an active member of SIR, CIRSE, ESR, and APSCVIR.
Recognizing the future benefits that the LIBERTY Robotic System can bring to his patients, Dr. Vidal led a successful feasibility pre-clinical trial for the LIBERTY Robotic System at his lab located at LiiE, and the positive results of the trial prompted him to join the Company’s SAB where his experience and expertise can be leveraged to help ensure the LIBERTY Robotic System is available to meet the future needs of the interventional radiologist community and their patients.
“We welcome Dr. Vidal as a global leader in the interventional radiology community, and his addition to our SAB is yet another milestone in our vision to allow access to the benefits that the LIBERTY Robotic System is expected to deliver to many patients and their healthcare providers globally,” commented Harel Gadot, Chairman, CEO, and President of Microbot Medical. “It is always reassuring when top Key Opinion Leaders like Dr. Vidal are excited to join our SAB after their personal experience using our technology, and we believe that the team of scientific leaders we established over the last few months will help position us for a successful regulatory process, both for FDA and CE, and eventually to lead to global commercialization of the world’s first fully disposable endovascular robotic system.”
“I was immediately drawn to the LIBERTY Robotic System due to its novel form factor and unique capabilities, and once I was able to experience it first-hand, it confirmed my initial views of its future potential,” commented Dr. Vidal. “The Microbot Medical team has achieved a great deal getting it to this point, and my goal is to ensure success at each of the next regulatory steps. I believe my fellow interventional radiologists, as well as the hospital administrators, will gravitate to the LIBERTY Robotic System when it becomes commercially available because I believe it addresses many clinical and financial needs.”
Source: Microbot Medical.